Brief: Matinas Biopharma Announces Collaboration With National Resilience To Explore And Evaluate Novel LNC Platform Delivery Technology For Certain Nucleic Acids
12/01/2023 12:11
Jan 12 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA ANNOUNCES COLLABORATION WITH NATIONAL
RESILIENCE TO EXPLORE AND EVALUATE NOVEL LNC PLATFORM DELIVERY
TECHNOLOGY FOR CERTAIN NUCLEIC ACIDS
Source text for Eikon: ID:nGNX1Cxv09
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing
Brief: Matinas Biopharma Holdings Inc Keith Kucinski Resigns As CFO Effective January 17, 2026
Brief: Matinas Biopharma Holdings Inc - CFO Keith Kucinski Resigns Effective January 17, 2026 - SEC Filing
Brief: Matinas Biopharma Holdings Eric Ende Resigns As Chairman Of Matinas Biopharma
Brief: Matinas BioPharma Appoints Seasoned Biotech Leaders To Board Of Directors